Risk of hepatitis B virus reactivation during immunosuppressive treatment
Yazarlar (3)
Prof. Dr. Ayşe KEFELİ
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Prof. Dr. Umut Safiye ŞAY COŞKUN
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SCOPUS dergilerinde yayınlanan tam makale |
| Dergi Adı | EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES |
| Dergi ISSN | 2284-0729 |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Makale Dili | İngilizce |
| Basım Tarihi | 07-2023 |
| Cilt No | 27 |
| Sayı | 7 |
| Sayfalar | 2823 / 2831 |
| DOI Numarası | 10.26355/eurrev_202304_31913. |
| Makale Linki | https://pubmed.ncbi.nlm.nih.gov/37070882/ |
| Özet |
| In this study, we aimed to rate Hepatitis B Virus (HBV) reactivation, risk factors for reactivation and compare the efficacy of prophylactic antiviral therapy in patients who initiated immunosuppressive therapy. A total of 177 patients with Chronic Hepatitis B or resolved HBV infection who had received immunosuppressive treatment were analyzed in this retrospective study. Demographic features, relevant liver tests, prophylactic treatment type, duration of treatment, transaminase levels and HBV serology and clinical conditions were recorded from all patients who received prophylactic treatment. Eleven reactivation occurred in all groups. The mean age of patients who developed reactivation was statistically significantly lower (p=0.049). Three (27.3%) of the patients were male and 8 (72.7%) were female (p=0.66). Eight (36.36%) of 22 HB surface antigen (HBsAg) positive patients developed reactivation, 3 (155%) of 155 HBsAg negative patients developed reactivation. HBsAg positivity was determined as a risk factor for reactivation (p<0.001). There was no significant difference neither in reactivation, nor in the type of antiviral treatment (p=0.2) according to anti-HBs serology (p=0.366). As a result, early age, baseline HBsAg positivity, moderate risk group, baseline HBV DNA positivity were associated with reactivation. Gender, immunosuppressive therapy type, preemptive antiviral therapy type, and anti-HBs titers were not associated with reactivation. |
| Anahtar Kelimeler |
| Immunosuppressive treatment | HBV reactivation | Entecavir | Tenofovir |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 1 |